vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $253.4M, roughly 1.1× Palomar Holdings, Inc.). On growth, Palomar Holdings, Inc. posted the faster year-over-year revenue change (62.7% vs 39.4%). Palomar Holdings, Inc. produced more free cash flow last quarter ($409.0M vs $-54.2M). Over the past eight quarters, Palomar Holdings, Inc.'s revenue compounded faster (46.2% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
GH vs PLMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $253.4M |
| Net Profit | $-128.5M | — |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 28.7% |
| Net Margin | -45.7% | — |
| Revenue YoY | 39.4% | 62.7% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $253.4M | ||
| Q3 25 | $265.2M | $244.7M | ||
| Q2 25 | $232.1M | $203.3M | ||
| Q1 25 | $203.5M | $174.6M | ||
| Q4 24 | $201.8M | $155.8M | ||
| Q3 24 | $191.5M | $148.5M | ||
| Q2 24 | $177.2M | $131.1M | ||
| Q1 24 | $168.5M | $118.5M |
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $51.5M | ||
| Q2 25 | $-99.9M | $46.5M | ||
| Q1 25 | $-95.2M | $42.9M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $30.5M | ||
| Q2 24 | $-102.6M | $25.7M | ||
| Q1 24 | $-115.0M | $26.4M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 28.7% | ||
| Q3 25 | -37.3% | 27.4% | ||
| Q2 25 | -45.9% | 29.5% | ||
| Q1 25 | -54.6% | 30.8% | ||
| Q4 24 | -62.4% | 28.9% | ||
| Q3 24 | -61.3% | 25.9% | ||
| Q2 24 | -56.8% | 25.5% | ||
| Q1 24 | -59.2% | 29.0% |
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | 21.0% | ||
| Q2 25 | -43.0% | 22.9% | ||
| Q1 25 | -46.8% | 24.6% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | 20.5% | ||
| Q2 24 | -57.9% | 19.6% | ||
| Q1 24 | -68.2% | 22.3% |
| Q4 25 | $-1.01 | $2.05 | ||
| Q3 25 | $-0.74 | $1.87 | ||
| Q2 25 | $-0.80 | $1.68 | ||
| Q1 25 | $-0.77 | $1.57 | ||
| Q4 24 | $-0.90 | $1.29 | ||
| Q3 24 | $-0.88 | $1.15 | ||
| Q2 24 | $-0.84 | $1.00 | ||
| Q1 24 | $-0.94 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $106.9M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $942.7M |
| Total Assets | $2.0B | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $106.9M | ||
| Q3 25 | $580.0M | $111.7M | ||
| Q2 25 | $629.1M | $81.3M | ||
| Q1 25 | $698.6M | $119.3M | ||
| Q4 24 | $525.5M | $80.4M | ||
| Q3 24 | $585.0M | $86.5M | ||
| Q2 24 | $933.7M | $47.8M | ||
| Q1 24 | $1.0B | $61.4M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $942.7M | ||
| Q3 25 | $-354.5M | $878.1M | ||
| Q2 25 | $-305.5M | $847.2M | ||
| Q1 25 | $-250.8M | $790.4M | ||
| Q4 24 | $-139.6M | $729.0M | ||
| Q3 24 | $-60.1M | $703.3M | ||
| Q2 24 | $-1.6M | $532.6M | ||
| Q1 24 | $68.3M | $501.7M |
| Q4 25 | $2.0B | $3.1B | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.3B | $2.8B | ||
| Q1 25 | $1.3B | $2.4B | ||
| Q4 24 | $1.5B | $2.3B | ||
| Q3 24 | $1.5B | $2.3B | ||
| Q2 24 | $1.6B | $2.0B | ||
| Q1 24 | $1.7B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $409.1M |
| Free Cash FlowOCF − Capex | $-54.2M | $409.0M |
| FCF MarginFCF / Revenue | -19.3% | 161.4% |
| Capex IntensityCapex / Revenue | 9.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $409.1M | ||
| Q3 25 | $-35.4M | $83.6M | ||
| Q2 25 | $-60.3M | $120.9M | ||
| Q1 25 | $-62.7M | $87.2M | ||
| Q4 24 | $-64.5M | $261.2M | ||
| Q3 24 | $-51.1M | $100.3M | ||
| Q2 24 | $-94.0M | $55.1M | ||
| Q1 24 | $-30.3M | $33.1M |
| Q4 25 | $-54.2M | $409.0M | ||
| Q3 25 | $-45.8M | $83.6M | ||
| Q2 25 | $-65.9M | $120.8M | ||
| Q1 25 | $-67.1M | $87.1M | ||
| Q4 24 | $-83.4M | $260.9M | ||
| Q3 24 | $-55.3M | $100.1M | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | 161.4% | ||
| Q3 25 | -17.3% | 34.2% | ||
| Q2 25 | -28.4% | 59.4% | ||
| Q1 25 | -33.0% | 49.9% | ||
| Q4 24 | -41.3% | 167.5% | ||
| Q3 24 | -28.9% | 67.4% | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | 0.1% | ||
| Q3 25 | 3.9% | 0.0% | ||
| Q2 25 | 2.4% | 0.0% | ||
| Q1 25 | 2.2% | 0.0% | ||
| Q4 24 | 9.4% | 0.2% | ||
| Q3 24 | 2.2% | 0.1% | ||
| Q2 24 | 2.9% | 0.0% | ||
| Q1 24 | 4.1% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.63× | ||
| Q2 25 | — | 2.60× | ||
| Q1 25 | — | 2.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.29× | ||
| Q2 24 | — | 2.14× | ||
| Q1 24 | — | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PLMR
Segment breakdown not available.
